bevacizumab,atezolizumab
roche
['bevacizumab', 'atezo']
adjuvant treatment with atezolizumab and bevacizumab prolongs recurrence-free survival, when compared with active surveillance, in patients with hepatocellular carcinoma, a phase 3 study presented at aacr 2023 suggests. #aacr23 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.